Trametinib

Description: Trametinib (GSK1120212) is a MEK inhibitor that inhibits MEK1 and MEK2 (IC50=0.7/0.9 nM) with ATP non-competitive and oral activity. Trametinib activates autophagy and induces apoptosis. Target: Apoptosis, MEK, Autophagy. Smiles: N(C1=C2C(N(C(=O)N(C2=O)C3CC3)C4=CC(NC(C)=O)=CC=C4)=C(C)C(=O)N1C)C5=C(F)C=C(I)C=C5. References: Wabitsch S, et al. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cell Mol Gastroenterol Hepatol. 2021,12(3):1166-1178.